Mangoceuticals Q3 10-Q: $8.3M Nine-Month Loss, $659K Cash, Going Concern Doubt
MGRX is trading near its 52-week low of $0.15 (8.0% above the low).
Summary
Mangoceuticals ended Q3 with $659,258 of cash against an $8.3M nine-month loss and a reiterated going concern warning, leaving it dependent on further dilutive financing while it works to cure its Nasdaq bid-price deficiency.
Key Events · Earnings and Guidance · MGRX
-
Cash Drops to $659,258
Cash and equivalents fell from $1,486,338 at December 31, 2025 to $659,258 at September 30, 2026, a $827,577 decline driven by $2,721,577 of operating cash burn.
-
Nine-Month Loss of $8.3M
Net loss was $8,269,591 for the nine months ended September 30, 2026 versus $17,874,085 a year earlier, with the improvement driven mainly by lower stock-based compensation of $4,268,241 versus $10,767,717.
-
Going Concern Doubt Reiterated
Management states current capital resources are not expected to fund operations for the next 12 months and that additional equity or debt financing, which may cause significant dilution, is required.
-
Nasdaq Bid-Price Deficiency Persists
The company remains below the $1.00 minimum bid price; Nasdaq granted a second compliance period through February 1, 2027, and the company has said it may effect a reverse stock split to cure the deficiency.
Analysis · MGRX · Industrial Applications And Services
Cash burn has left the company with $659,258 at September 30 versus $1,486,338 at year-end, while nine-month losses ran $8,269,591 and the accumulated deficit reached $48,916,795. Management explicitly says current resources are not enough to fund operations for the next 12 months, so another raise is required — and equity raises here have been deeply dilutive. The Nasdaq bid-price deficiency remains unresolved, with a second compliance period running to February 1, 2027 and a reverse split on the table. The one offset is the $1,750,000 raised by selling 18.92% of the MangoRx IP patent subsidiary, which brought in cash and USDT but also handed away a slice of the core patent asset.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MGRX was trading at $0.16 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.6M. The 52-week trading range was $0.15 to $1.49. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.